Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.58 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.49 |
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17812511 | 1.00 | NAAA (0.58) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL42509 | 1.00 | NAAA (0.58) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL1400502 | 1.00 | NAAA (0.58) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL14522676 | 1.00 | NAAA (0.58) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL1218314 | 1.00 | NAAA (0.58) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL9410611 | 1.00 | NAAA (0.58) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL1218319 | 1.00 | NAAA (0.58) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL2430831 | 1.00 | NAAA (0.58) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL43835 | 1.00 | NAAA (0.58) | NAAARAD52NPSR1FAAHDGKA | |
| SCHEMBL28058 | 1.00 | NAAA (0.58) | NAAARAD52NPSR1FAAHDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117969846-A | Galectin 3 detection kit and preparation method and application thereof | 神州医疗生物科技(北京)有限公司 | 2024-05-03 | — | — | CN | claimed |
| CN-117866638-A | Etching solution for removing high-doping-amount silicon in different doped silicon laminated layers and using method thereof | 湖北兴福电子材料股份有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-113289767-A | Micro-fine particle rutile efficient combined collector and preparation method and application thereof | 中南大学 | 2021-08-24 | — | — | CN | claimed |
| CN-101198308-A | Foamable alcohol compositions, systems and methods of use | 3M INNOVATIVE PROPERTIES CO (US) | 2008-06-11 | — | — | CN | claimed |
| US-12577373-B2 | Carbodiimide composition, curing agent composition, coating composition and resin cured product | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2026-03-17 | — | — | US | disclosed |
| US-20260055285-A1 | PLASMONIC INKS WITH VIVID COLORS | SOCIéTé BIC (FR) | 2026-02-26 | — | — | US | disclosed |
| WO-2025261968-A1 | ALKYLESTER OF ANDIROBA OIL | BASF SE (DE) | 2025-12-26 | — | — | WO | disclosed |
| US-12497525-B2 | Process of preparation of an aqueous gel ink with fixed color comprising gold nanoparticles | SOCIéTé BIC (FR) | 2025-12-16 | — | — | US | disclosed |
| US-12496264-B2 | Process for treating human transpiration using a cation and an anion in presence of a modulator | L'OREAL (FR) | 2025-12-16 | — | — | US | disclosed |
| EP-4267078-B1 | PROCESS FOR TREATING HUMAN PERSPIRATION AND BODY ODORS USING MAGNESIUM OXIDE AND A PHOSPHATE SALT | OREAL (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4637692-A1 | COLOR STABILIZATION OF FORMULAE WITH AN INDOLE | Unilever IP Holdings B.V. (NL) | 2025-10-29 | — | — | EP | disclosed |
| EP-4637690-A1 | OIL-CONTINUOUS COSMETIC COMPOSITION | Unilever IP Holdings B.V. (NL) | 2025-10-29 | — | — | EP | disclosed |
| EP-0517371-A2 | Hair growth composition containing citric acid esters | UNILEVER PLC (GB) | 1992-12-09 | — | — | EP | disclosed |
| EP-0514067-A1 | Cosmetic composition | UNILEVER PLC (GB) | 1992-11-19 | — | — | EP | disclosed |
| US-5157089-A | Citric ester diluents | HI-TEK POLYMERS, INC. (US) | 1992-10-20 | — | — | US | disclosed |
| US-5089658-A | Pigment grinding vehicles | HI-TEK POLYMERS, INC. (US) | 1992-02-18 | — | — | US | disclosed |
| EP-0437114-A1 | Shampoo composition | UNILEVER PLC (GB) | 1991-07-17 | — | — | EP | disclosed |
| EP-0361789-A2 | Citric ester diluents | HI-TEK POLYMERS, INC. (US) | 1990-04-04 | — | — | EP | disclosed |
| US-4572740-A | Citric acid esters as blowing and nucleating agents in the processing plastics | BOEHRINGER INGELHEIM KG (DE) | 1986-02-25 | — | — | US | disclosed |
| US-4508746-A | ESTER OF TRICARBALYIC ACID | CPC INTERNATIONAL INC. (US) | 1985-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12496264-B2 | Process for treating human transpiration using a cation and an anion in presence of a modulator | TYR, SLC26A4, SLC6A12 | NAAA 776/4885RAD52 4442/4885NPSR1 573/4885 |
| US-20260055285-A1 | PLASMONIC INKS WITH VIVID COLORS | MKI67, WNT3, WDR3 | NAAA 4356/4885RAD52 2060/4885NPSR1 4831/4885 |
| US-12577373-B2 | Carbodiimide composition, curing agent composition, coating composition and resin cured product | CD38, PARP9, MCCC2 | NAAA 757/4885RAD52 1397/4885NPSR1 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.